Status: Program paused due to pandemic. Anticipate restarting the program in early 2022.

Strategy: Personalized vaccine design based on information from the patient's own tumour.

Designed to generate strong T-cell responses that aim to kill cancer cells and destroy tumours.

Learn the inspiring story behind Providence Therapeutics and the technology that makes it all possible by watching the video below.

Providence’s lead personalized mRNA cancer vaccine will treat women with advanced ovarian cancer before expanding into other cancers including brain and breast cancer. This trial will be an open-label, dose-escalation, safety study. Primary endpoints will be safety, tolerance, and pharmacodynamics. Secondary endpoints will include objective response, time to progression, and immune response. The study will be led by Dr. Amit Oza in Toronto.

In addition to PTX-101, Providence is currently working on next-generation mRNA cancer vaccines based on novel ideas generated by our scientific advisory board. These projects are in the discovery phase. Providence plans to bring them to the clinic as soon as possible to help change and improve the standard of care in multiple cancer types.



We are part of the mRNA Revolution.   

Cancer Types


Ovarian Cancer

1 in 75 will be diagnosed

In their lifetime, 1 in 75 women will be diagnosed with ovarian cancer, with over 25,000 new cases every year in the US and Canada. Advanced ovarian cancer, which is increasing in incidence, is a disease of high unmet medical need, the five-year survival rate is less than 20% and additional effective therapies are in great need.


The current five-year survival rate is less than 10%

Glioblastoma is the most common aggressive form of advanced brain tumour with 15,000 new cases in Canada and the US every year. There have been no significant improvements in glioblastoma treatments in over 20 years and the current five-year survival rate is less than 10%. There is expected to be an annual market of over $US 2 billion by 2022.

Breast Cancer

300,000 new cases a year

Breast cancer is one of the most common types of cancer with nearly 300,000 new cases a year in Canada and the US. This equates to 1 in 8 women being diagnosed with breast cancer in their lifetime. Certain types of breast cancer now have effective treatments, but there are other segments of the disease, for example, triple-negative breast cancer, that still have a very poor unmet medical need. It will be these segments that Providence will aim to address with our PTX-101 cancer vaccine.